DNDN

9 Biotech Buyout Players to Watch

The deal between Human Genome Sciences and GlaxoSmithKline is just the most recent of big pharma buyouts -- and these biotech players could be next. More 

Rallying on Stimulus Hopes: Thursday’s IP Market Recap

Will higher jobless claims and scant inflation mean QE3? Investors are counting on the Fed to make more moves. More 

Great Day for Dividends! — Wednesday’s IP Market Recap

Dividend news out of Dell, Target and Caterpillar wasn't enough to overcome broader macroeconomic news Wednesday, and the indices headed south. More 

Cue the Biotech M&A Attack!

A rush of buyout activity in biotechs like Human Genome and Illumina could produce more frenzied M&A deals down the road. More 

Analysts Run the Apple Asylum — Tuesday’s IP Market Recap

Price targets keep climbing to the moon: $715, $910 -- even $1,001. More 

Investors Bid Up Homebuilders, Energy Stocks — Monday’s IP Market Recap

A rise in pending home sales lifts equities to a flat day overall. Lowe's joins the homebuilders' rise for the day. More 

4 Stocks to Watch on Dendreon Earnings

Here's a look at how to trade Dendreon on Monday's earnings report, as well as similar smaller companies that tend to move when DNDN moves. More